Hormone therapy plus targeted prostate treatment for intermediate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study tests whether combining hormone treatment (androgen deprivation therapy) with focal ablation (targeted destruction of prostate tissue) controls intermediate-risk prostate cancer. It may help some men avoid or reduce more aggressive treatment, while still aiming for cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have intermediate-risk prostate cancer (not low-risk or very advanced).
- Your prostate cancer has not spread outside the prostate and there is no spread to lymph nodes or bones on recent scans.
- You must choose focal (targeted) prostate treatment as your plan for treating your cancer.
- You must be able to undergo general anesthesia and the targeted prostate procedure (focal ablation).
- You must have enough blood and organ function for treatment (for example, hemoglobin, platelets, kidney and liver tests) and a good enough overall activity level.
- You must be male age 18 or older and willing to sign consent; if sexually active with a pregnancy-capable partner, you must use condoms plus a reliable birth-control method during treatment and for 3 months after the last hormone shot.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gentler treatment called focal therapy that targets only the part of the prostate with cancer. It's for men whose prostate cancer has a Gleason score of 7, low PSA, and hasn't spread outside the prostate.
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
This study tracks men with intermediate-risk prostate cancer who had a newer, targeted treatment that only treats the cancer area, not the whole prostate. It aims to see how well these treatments work in real life and may help guide future care.
This trial tests combining radiation therapy with two hormone-blocking drugs (darolutamide and degarelix) to treat intermediate-risk prostate cancer. The goal is to see if this combination is more effective and safe than radiation alone.
This study tests a targeted treatment for prostate cancer that aims to treat only the cancer while sparing healthy tissue. It may be an option for men with low to medium risk prostate cancer.
This trial tests a treatment that uses high-intensity focused ultrasound to target and destroy cancer cells in the prostate, combined with a newer hormone therapy. This approach may help control advanced prostate cancer and improve outcomes.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.